Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/karger/isolated-tuberculous-epididymitis-a-rare-complication-after-oRbFHVEVwB
References
References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.
- Publisher
- Karger
- Copyright
- © 2011 S. Karger AG, Basel
- ISSN
- 1661-7649
- eISSN
- 1661-7657
- DOI
- 10.1159/000327461
- Publisher site
- See Article on Publisher Site
Abstract
Intravesical instillation of Bacillus Calmette-Guerin (BCG) is the most commonly used immunotherapeutic adjuvant therapy for superficial bladder carcinoma. BCG is a live attenuated vaccine of Mycobacterium bovus which has been shown to decrease tumor recurrence rate, delay tumor progression, and improve overall survival. Intravesical BCG is well tolerated, with a complication rate under 5%. A literature review revealed tuberculous epididymitis to be a rare adverse event following intravesical BCG therapy. We report the case of an 82-year-old male undergoing BCG therapy for superficial transitional cell carcinoma of the bladder who presented with a painless right testicular mass. The patient had no previous history of tuberculosis. He successfully underwent a right orchiectomy and histopathology confirmed M. bovis as the etiological agent.
Journal
Current Urology – Karger
Published: Jan 1, 2011
Keywords: Bacillus Calmette-Guerin; Bladder cancer; Tuberculous epididymitis